Scarpa 1997.

Methods	DESIGN Within‐patient Participant delivery ALLOCATION Random Method of randomisation: not reported; tubes labelled left or right and with participant ID number and tube ID number Concealment: unclear BLINDING Double‐blind (participant/investigator) WITHDRAWAL/DROPOUT Described
Participants	N: 157 Treatment duration: 6 wks; FU: 7 wks LF: 23 (14.6%) BC: yes Age: 49 (15SD; N = 134) Gender (per cent men): 65.6% (N = 157) Severity: TSS (0 to 12) = 7.7 INCLUSION CRITERIA Stable chronic plaque psoriasis Symmetrical lesions In‐ and outpatients EXCLUSION CRITERIA Pregnancy Lactation Inadequate contraception Recent systemic, light, or topical therapy Severe renal failure Liver and cardiac dysfunction Hypercalcemia Hyperphosphoremia AIDS Drug addiction
Interventions	Tacalcitol ointment 4 mcg/g OD (T) Placebo (vehicle) OD (P)
Outcomes	Signs: scaling; erythema; scaling TSS (0 to 12) Patient compliance (tube count; tube contents)
Notes	The trial did not report sponsorship, but Istituto Gentili SpA provided medications and appeared to have undertaken the randomisation. There was SD imputation (TSS).
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	The trial reported insufficient details.
Blinding (performance bias and detection bias) All outcomes	Low risk	The trial was double‐blind (participant/investigator).
Randomisation method reported	Unclear risk	The trial did not report this.
Loss to follow up	Low risk	14.6%
Baseline assessments	Low risk	‐
Baseline comparability demonstrated	Low risk	‐